Omnicell (NASDAQ:OMCL) had its target price raised by investment analysts at Benchmark from $155.00 to $160.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Benchmark's price target points to a potential upside of 14.45% from the company's previous close.
A number of other brokerages have also commented on OMCL. Craig Hallum boosted their price target on shares of Omnicell from $100.00 to $142.00 and gave the company a "buy" rating in a research note on Thursday, January 14th. Piper Sandler boosted their price target on shares of Omnicell from $147.00 to $152.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, TheStreet lowered shares of Omnicell from a "b" rating to a "c+" rating in a research note on Friday, April 30th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of "Buy" and a consensus target price of $120.50.
NASDAQ:OMCL opened at $139.80 on Thursday. The company has a fifty day moving average of $137.87 and a 200-day moving average of $120.09. The firm has a market capitalization of $6.04 billion, a P/E ratio of 160.69, a P/E/G ratio of 3.68 and a beta of 1.04. The company has a quick ratio of 3.68, a current ratio of 4.12 and a debt-to-equity ratio of 0.50. Omnicell has a twelve month low of $56.16 and a twelve month high of $146.99.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, April 29th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.17. Omnicell had a net margin of 4.25% and a return on equity of 7.96%. On average, analysts anticipate that Omnicell will post 1.71 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Vantage Consulting Group Inc bought a new stake in shares of Omnicell in the 4th quarter worth $46,000. Archer Investment Corp grew its stake in shares of Omnicell by 50.0% in the 4th quarter. Archer Investment Corp now owns 450 shares of the company's stock worth $54,000 after acquiring an additional 150 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Omnicell by 21.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 522 shares of the company's stock worth $63,000 after buying an additional 93 shares during the last quarter. Fieldpoint Private Securities LLC boosted its holdings in shares of Omnicell by 247.1% in the 1st quarter. Fieldpoint Private Securities LLC now owns 486 shares of the company's stock worth $63,000 after buying an additional 346 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Omnicell by 37.8% in the 4th quarter. Parallel Advisors LLC now owns 558 shares of the company's stock worth $67,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 99.24% of the company's stock.
Omnicell, Inc, together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: What moving averages are used to define a golden cross?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Momentum Indicator: Relative Strength Index7 Stocks That Cathie Wood is Buying And You Should Too
If you’re an investor that likes to go with the “hot hand,” then they don’t get much hotter than Cathie Wood. The founder and CEO of ARK Investment Management delivered returns of over 100% in all five of her firm’s exchange-traded funds (ETFs) in 2020.
The names of her funds showcase some of the hottest emerging growth trends in the market: financial technology (fintech), genomic revolution, innovation, autonomous technology/robotics, and next generation internet.
As you would expect, these funds contain some of the hottest growth stocks from the past year. And in the aftermath of the tech selloff, Wood is not backing away. In fact, she’s doubling down on her strategy. It might not be exactly a matter of being greedy while others are fearful; perhaps more like being prepared while others are distracted.
But the other thing about Wood’s selections is that many of them are not obscure names. These are companies that were among the hottest names in 2020. Wood simply believes that they still have room to run. And that’s one reason you should consider making them a part of your portfolio.
In this special presentation, we’re giving you just seven of the stocks that Cathie Wood is buying or has bought recently. We’ve attempted to pick out at least one stock from each of the ARK ETFs. As with any investment decision, it’s important that you perform your own research before making a decision.
View the "7 Stocks That Cathie Wood is Buying And You Should Too"